Summary PEP-Therapy SAS (PEP-Therapy) is a medical biotechnology company that develops targeted therapies for the treatment of cancer.The company develops cell penetrating and interfering peptides for the intracellular delivery of targeted therapies.
Its pipeline products include PEP-010.PEP-Therapy’s PEP-010 includes penetrating shuttle to deliver the active peptide into the cell, and an interfering active peptide blocking Caspase-9/PP2A interaction.
The company’s product is used for the treatment of triple-negative breast cancer, lung and ovary cancers, and chronic lymphocytic leukemia.It also conducts clinical trials and licenses the novel therapeutic products and companion biomarkers to both pharmaceutical and biotech companies for their development and commercialization.
PEP-Therapy is headquartered in Paris, France.
PEP-Therapy SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2020 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes....
P2X Purinoceptor 3 - Pipeline Review, H1 2020 Summary According to the recently published report ’P2X Purinoceptor 3 – Pipeline Review, H1 2020’; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining...
Survival Motor Neuron Protein - Pipeline Review, H1 2020 Summary Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) – Survival of motor neuron or survival motor neuron (SMN) is a protein encoded by the SMN1 and SMN2 genes. The SMN complex plays a catalyst role in the assembly...
225 pages •
By Asia Market Information & Development Company
• May 2020
China’s demand for HIV Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. Snapshot Overview – Gilead’s sales will remain broadly stable over the medium term due to its strong HIV franchise, but will decline later in the forecast period due to patent expirations of key therapy backbones. Key...
91 pages •
By Asia Market Information & Development Company
• May 2020
This study focuses on China’s HIV Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major...
Pain Management Devices - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Pain Management Devices - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Pain Management Devices pipeline products with comparative analysis of the...
Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion Summary This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales.The number of contract service...
200 pages •
By The Business Research Company
• Jul 2020
Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited, and Orthosera Kft. The global convalescent plasma therapy market is expected to grow from $20.3 million in 2019 to $26.4 million by the end of 2020 at a compound...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.